Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

This is not the Jedi you're thinking of. This Jedi is a receptor that helps clear away dead neurons during development, and its loss changes the activity of dorsal root ganglia neurons, which could have implications for treating chronic pain.

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

Vanderbilt biochemists got unexpected results when they used their new approach to explore the role of DNA methylation in gene regulation.

D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.

A newly identified protein interaction that affects cell cycle regulation may be an attractive target for cancer therapy.

A drug used to treat and prevent HIV/AIDS is showing promise as a potential therapy for Alzheimer’s disease.